INmune Bio adds two directors with rare-disease and business-development backgrounds

INmune Bio Inc. announced on September 14, 2026 that its Board of Directors had appointed R. Duane Clark II and James Sapirstein, R.Ph., MBA, as directors, effective September 8, 2026. The board increased its size to seven members and appointed both men to serve until the next annual election.¹ Both were also named to the board's Nominating and Corporate Governance Committee.¹

Clark, 63, currently holds a senior rare-disease leadership post at Sanofi. He is General Manager of U.S. Rare Diseases at Sanofi, overseeing a multi-billion-dollar business unit that includes seven rare-disease brands, with responsibility for the unit's profits and losses.¹ Earlier in his career, he ran Sanofi's multiple sclerosis business in the U.K. and Ireland and held commercial and business-development positions at CTI Clinical Trial & Consulting Services, Encysive Pharmaceuticals, Astellas Pharma, Ortho Biotech and Marion Laboratories.¹

Sapirstein, 65, brings a background in licensing and public-company leadership. He is currently CEO of Cocrystal Pharma, Inc. (Nasdaq: COCP) and CEO and Chairman of the private company 8 Prime Biosciences.¹ Before those roles, he served as CEO and Chairman of Entero Therapeutics, Inc., trading as Nasdaq: ENTO, from October 2019 to February 2025; that company has since been renamed GridAI Technologies Corp. and trades as Nasdaq: GRDX. Sapirstein remained a consultant to the company through March 2026.¹ He also serves as Executive Chairman of Onconetix, Inc. (Nasdaq: ONCO) and as a director of ZyVersa Therapeutics, Inc. (OTC Pink: ZVSA).¹

Compensation for both new directors includes options to purchase 100,000 shares of common stock under the company's 2021 Stock Incentive Plan, plus an annual cash retainer of $50,000 payable quarterly.¹ The stock options vest monthly over three years from the grant date.¹